FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247101454> ?p ?o ?g. }

• W2247101454 endingPage "387" @default.
• W2247101454 startingPage "387" @default.
• W2247101454 abstract "387 Background: Pancreatic cancer (PC) outcomes remain poor, recent series show approximately 37% of patients achieve R0 resection (all margins ≥ 1mm) for resectable disease. Recent data in metastatic disease shows that nab-paclitaxel (nab-PC) and gemcitabine (GEM) chemotherapy (CX) is an active regimen. We aimed to determine the feasibility and R0 resection rate with peri-operative nab-PC and GEM for resectable PC. Methods: A multicentre, single arm, phase 2 trial. Patients with operable PC received 2 cycles of neo-adjuvant GEM 1000mg/m 2 and nab-PC 125mg/m 2 CX on days 1, 8 and 15 of a 28 day cycle followed by surgical resection and then 4 cycles of post-operative CX. The primary endpoint was R0 resection with the aim to assess if a rate of 85% could be achieved. Secondary endpoints included feasibility, toxicity, pathological response (College of American Pathologists Cancer Reporting Protocol for Exocrine Pancreatic Cancer, 2009), recurrence and survival. Results: Forty-one patients were enrolled from 2012-14. Median age was 65 (range 43-79), 41% male, 49% stage I and 51% stage II. Twenty nine (71%) patients underwent resection with evaluable cancer: 1 did not have proven cancer on central pathology review; 5 did not go to surgery (2 disease progression, 2 refused surgery, 1 due to cholangitis); and in 6 patients surgery was abandoned (unresectable disease). No deaths were surgery-related. Median tumor size was 27.5mm (IQR = 25-35). Pre-operative GEM and nab-PC produced an R0 rate of 52% (15/29) (95% CI 34-69%). 15/29 (52%) of resected tumors showed grade 0-2 tumor regression grade. Twenty-nine patients (71%) experienced >1 grade 3/4 toxicities (total 52 events) during pre-operative CX, neutropenia (46%) being most frequent with 8% febrile neutropenia. 39/41 (95%) patients received 2 cycles of pre-operative CX. Conclusions: Peri-operative GEM and nab-PC CX is feasible and well tolerated. The pre-operative regimen was associated with an R0 resection rate comparable or higher than surgical series without pre-operative therapy, although the primary endpoint of 85% could not be met. The value of this regimen will also depend on longer term outcomes related to recurrence and survival. Clinical trial information: 12611000848909." @default.
• W2247101454 created "2016-06-24" @default.
• W2247101454 creator A5003030864 @default.
• W2247101454 creator A5005797468 @default.
• W2247101454 creator A5010021791 @default.
• W2247101454 creator A5011795261 @default.
• W2247101454 creator A5014681581 @default.
• W2247101454 creator A5014740620 @default.
• W2247101454 creator A5015610217 @default.
• W2247101454 creator A5020108110 @default.
• W2247101454 creator A5023743013 @default.
• W2247101454 creator A5034486818 @default.
• W2247101454 creator A5037570113 @default.
• W2247101454 creator A5048216105 @default.
• W2247101454 creator A5056858025 @default.
• W2247101454 creator A5072890476 @default.
• W2247101454 creator A5072970117 @default.
• W2247101454 creator A5078484307 @default.
• W2247101454 creator A5081680405 @default.
• W2247101454 creator A5085372050 @default.
• W2247101454 creator A5086605611 @default.
• W2247101454 creator A5086908096 @default.
• W2247101454 date "2015-01-20" @default.
• W2247101454 modified "2023-09-27" @default.
• W2247101454 title "A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study." @default.
• W2247101454 doi "https://doi.org/10.1200/jco.2015.33.3_suppl.387" @default.
• W2247101454 hasPublicationYear "2015" @default.
• W2247101454 type Work @default.
• W2247101454 sameAs 2247101454 @default.
• W2247101454 citedByCount "4" @default.
• W2247101454 countsByYear W22471014542015 @default.
• W2247101454 countsByYear W22471014542016 @default.
• W2247101454 countsByYear W22471014542018 @default.
• W2247101454 crossrefType "journal-article" @default.
• W2247101454 hasAuthorship W2247101454A5003030864 @default.
• W2247101454 hasAuthorship W2247101454A5005797468 @default.
• W2247101454 hasAuthorship W2247101454A5010021791 @default.
• W2247101454 hasAuthorship W2247101454A5011795261 @default.
• W2247101454 hasAuthorship W2247101454A5014681581 @default.
• W2247101454 hasAuthorship W2247101454A5014740620 @default.
• W2247101454 hasAuthorship W2247101454A5015610217 @default.
• W2247101454 hasAuthorship W2247101454A5020108110 @default.
• W2247101454 hasAuthorship W2247101454A5023743013 @default.
• W2247101454 hasAuthorship W2247101454A5034486818 @default.
• W2247101454 hasAuthorship W2247101454A5037570113 @default.
• W2247101454 hasAuthorship W2247101454A5048216105 @default.
• W2247101454 hasAuthorship W2247101454A5056858025 @default.
• W2247101454 hasAuthorship W2247101454A5072890476 @default.
• W2247101454 hasAuthorship W2247101454A5072970117 @default.
• W2247101454 hasAuthorship W2247101454A5078484307 @default.
• W2247101454 hasAuthorship W2247101454A5081680405 @default.
• W2247101454 hasAuthorship W2247101454A5085372050 @default.
• W2247101454 hasAuthorship W2247101454A5086605611 @default.
• W2247101454 hasAuthorship W2247101454A5086908096 @default.
• W2247101454 hasConcept C121608353 @default.
• W2247101454 hasConcept C126322002 @default.
• W2247101454 hasConcept C141071460 @default.
• W2247101454 hasConcept C143998085 @default.
• W2247101454 hasConcept C146357865 @default.
• W2247101454 hasConcept C151730666 @default.
• W2247101454 hasConcept C203092338 @default.
• W2247101454 hasConcept C2776694085 @default.
• W2247101454 hasConcept C2780210213 @default.
• W2247101454 hasConcept C2780258809 @default.
• W2247101454 hasConcept C2781413609 @default.
• W2247101454 hasConcept C31760486 @default.
• W2247101454 hasConcept C535046627 @default.
• W2247101454 hasConcept C71924100 @default.
• W2247101454 hasConcept C86803240 @default.
• W2247101454 hasConceptScore W2247101454C121608353 @default.
• W2247101454 hasConceptScore W2247101454C126322002 @default.
• W2247101454 hasConceptScore W2247101454C141071460 @default.
• W2247101454 hasConceptScore W2247101454C143998085 @default.
• W2247101454 hasConceptScore W2247101454C146357865 @default.
• W2247101454 hasConceptScore W2247101454C151730666 @default.
• W2247101454 hasConceptScore W2247101454C203092338 @default.
• W2247101454 hasConceptScore W2247101454C2776694085 @default.
• W2247101454 hasConceptScore W2247101454C2780210213 @default.
• W2247101454 hasConceptScore W2247101454C2780258809 @default.
• W2247101454 hasConceptScore W2247101454C2781413609 @default.
• W2247101454 hasConceptScore W2247101454C31760486 @default.
• W2247101454 hasConceptScore W2247101454C535046627 @default.
• W2247101454 hasConceptScore W2247101454C71924100 @default.
• W2247101454 hasConceptScore W2247101454C86803240 @default.
• W2247101454 hasIssue "3_suppl" @default.
• W2247101454 hasLocation W22471014541 @default.
• W2247101454 hasOpenAccess W2247101454 @default.
• W2247101454 hasPrimaryLocation W22471014541 @default.
• W2247101454 hasRelatedWork W114644245 @default.
• W2247101454 hasRelatedWork W2002483815 @default.
• W2247101454 hasRelatedWork W2024219304 @default.
• W2247101454 hasRelatedWork W2376347278 @default.
• W2247101454 hasRelatedWork W2403481407 @default.
• W2247101454 hasRelatedWork W2410090482 @default.
• W2247101454 hasRelatedWork W2414965726 @default.
• W2247101454 hasRelatedWork W3029364823 @default.
• W2247101454 hasRelatedWork W3097620325 @default.
• W2247101454 hasRelatedWork W4254486378 @default.

• next